Objectives To compare rates of typmanostomy tube insertions for otitis media with effusion with estimates of need in 2 countries.
O titis media is the most common childhood diagnosis with 2.2 million children affected before school age, and with the highest prevalence occurring between the ages of 6 months and 3 years. 1 In 90% of children, a middle ear effusion develops subsequently and in 40% it persists for more than 3 months.
1,2 Insertion of tympanostomy tubes (grommets) to relieve otitis media with effusion (OME) or reduce recurrent otitis media is the most common pediatric procedure in the US, accounting for more than 20% of all pediatric ambulatory surgery, with annual associated costs exceeding $5 billion. 3 Rates of tympanostomy tube insertion are known to vary across regions in the US, England, Canada, Finland, and Norway. [4] [5] [6] [7] [8] [9] [10] Although Black found that there was a reduction in the mean rate for England following clinical guidelines issued in the 1990s, which were already one-half the rate of the US, substantial variation in rates of treatment continued. 2, 6, [11] [12] [13] [14] This variation could be due to differences in need and preferences of patients, and, for this procedure, the preferences of their parents. However, using RAND-University of California at Los Angeles appropriateness criteria 7, 8 and patient data from chart reviews, a significant majority of US tympanostomy insertions were found to be inappropriate. For example, a key finding from a study of tympanostomy insertions in England 15 was the suggestion that there appeared to be both over-and undertreatment (ie, operations were carried out for patients who were unlikely to benefit and not performed in patients for whom benefit was likely).
In this study, we moved from descriptions of variations in rates of treatment to normative assessments, by developing estimates of "need" in terms of likely capacity to benefit in England and Northern New England (NNE). We used a model based on England's National Institute of Health and Care Excellence (NICE) guidelines, 16 which are similar to those developed by the American Academy of Pediatrics (AAP). 1 We postulated overuse and underuse of tympanostomy tubes in 2 countries with very different funding and organization of health care.
Methods
We measured the use of tympanostomy tubes in children ages 2-8 years residing in Maine, Vermont, and New Hampshire, and registered with the English National Health Service (NHS) during the period 2007-2010. For NNE we used pediatric allpayer administrative datasets limited to children with 1 or more months' enrollment in a Medicaid or commercial insurance plan that met state-level data-reporting mandates. 17 For England, private paying patients were not included. This study was approved by the Committee for the Protection of Human Subjects at Dartmouth College. In England, the use of secondary data in an anonymized and aggregated form does not require ethical approval.
We 4 These regions represent markets of pediatric surgical care. Overall, 67.6% of children residing within the areas received tubes from providers within the area. In England, rates are reported for residents of Primary Care Trusts (PCT; N = 151) that were defined geographically by the NHS. Privately financed procedures are not reported. Observed rates were calculated as the number of procedures divided by the study population within each region.
Calculating Expected Number of Tube Insertions
An epidemiologic model was developed to estimate "expected" tympanostomy tube placement.
15 OME usually is transitory and the expected benefit from ear tubes depends on the time lapsed from onset of diagnosis to when treatment is considered. 2, [18] [19] [20] [21] [22] [23] Our epidemiologic model unites 2 probabilities: age-specific incidence and the course of OME disease. The model starts with the population at risk of developing OME and includes the probability that a relative portion of those at risk will develop bilateral OME with hearing loss of +25 and +20 dB. The recovery rate determines the proportion of children with resolved OME and hearing loss, and so "returning" to the susceptible population. Patients for whom a diagnosis of OME is confirmed after 3 months of "watchful waiting" have a capacity to benefit (ie, improvement of hearing) from tympanostomy tubes and should be considered for surgical intervention according to NICE guidance and AAP guidelines. 1, 16 The probabilities are used in a Monte Carlo simulation (ie, through repeated sampling) to model the expected number of children with capacity to benefit from tympanostomy tubes for OME. We calculated expected incidence of bilateral OME with a hearing loss of both +25 and +20 dB with 10 000 iterations of the model to calculate 90% CI in the mean estimates.
We assume that 46% of children with bilateral OME will have a hearing threshold of +25 dB and 35% a hearing threshold of +20 dB. 15, 24 The US AAP guidelines recommend consideration of tympanostomy surgery with a +20 dB or greater threshold, and the English guidelines recommend surgery for a +25 dB or greater threshold. 1, 16 Both guidelines also suggest tube insertion for children with additional risk factors.
Model Validation
The above model parameters and incidence calculations were iteratively discussed and refined in consultation with a Project Steering Group at the London School of Economics and Political Science. 15 Participants included experts in audiology, otolaryngology, general practice, and epidemiology, and were invited to validate the model's components and overall accuracy. The group judged the model to be a judicious representation of the NICE care pathway and treatment process governing OME. The parameters 15 used in this study were unchanged.
Analyzing Utilization Differences
We calculated the difference between observed and expected incidence by geographic area by age. Expected and observed rates were aggregated across age groups, and the total difference was calculated by geographic area. Given that the observed number of pressure equalization tubes is based on actual tube placement, the observed counts are the same for each region in the observed to expected ratio (O:E), and the expected counts differ for 20 and 25 dB hearing loss. We calculated 95% CI for these ratios assuming a binomial distribution for observed counts and the expected counts as known constants. We used simple linear regression to test the association between rates of observed and expected tube insertions.
Results
From the administrative data we identified 6052 tympanostomy tubes provided for children in NNE, and 66 414 tubes for children in England over the study period. (Table I ) The mean age of children receiving tympanostomy tubes in NNE and England was 3.9 years and 4.9 years, respectively, and the majority was male (58.5% for NNE; 55.5% for England). The observed rate of tympanostomy tubes provided in England was 4.01 per 1000 child-years and 83% higher in NNE at 7.34 per 1000 child-years.
Regional rates of surgery differed widely in both countries. In NNE, observed incidence varied more than 3-fold across PSA (3.79 to 13.15 per 1000); in England, observed provision of tympanostomy tubes 0 more than 30-fold across PCT (0.45 to 14.45 per 1000). Using the +25 dB threshold, expected incidence for NNE (7.28 to 7.46 per 1000) and England
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Volume ■■ (7.33 to 7.70 per 1000) varied little. The +20 dB threshold yielded similarly low expected variation for both study areas (NNE: 9.57 to 9.81 per 1000; England: 9.63 to 10.25 per 1000) (not shown). Tables I-III (Tables II-III ; available at www.jpeds.com) presents net differences in expected to observed rates at both hearing thresholds for NNE and England. In NNE, the overall observed total number of insertions was close to the expected number for a +25 dB threshold (observed to expected difference −7; observed minus expected rate −0.01 per thousand; O:E 1.00). Using the +20 dB threshold, there were far fewer observed tube insertions than expected (observed to expected difference −1911; observed minus expected rate −3.27 per thousand; O:E 0.76). In England, the observed total number of insertions was much lower than expected for both hearing thresholds. Using the +25 dB guideline threshold, the observed to expected difference was −57 383; observed minus expected rate −3.41 per thousand; O:E 0.54. Using the +20 dB guideline threshold, the observed to expected difference was −96,291; observed minus expected rate −5.82 per thousand; O:E 0.41. Figure 1 depicts the small area differences in observed to expected incidence centered at a ratio of 1 (ie, no difference) across NNE and England with 95% CI. With a +25 dB threshold, the observed incidences were less than expected in all but 8 PCT, and higher than expected rates were observed in about one-half of the PSA. With a +20 dB threshold, there were fewer than expected in all but 2 in England and seven NNE areas.
There was a weak inverse relationship (Figure 2 ) between estimated need of tube insertion and observed rates (England P < .01, R 2 = 0.05; NNE P < .05, R 2 = 0.20); particularly for NNE, areas with relatively higher needs generally had lower observed rates.
Sensitivity Analyses
Although NNE is socioeconomically diverse, there are only small differences between rates of tympanostomy procedures between those insured by Medicaid (7.53 per 1000 person-years) and commercial (7.16 per 1000 per-years) insurance plans (Table IV) . There is no equivalent proxy for stratifying by socioeconomic risk at the individual level for England.
Discussion
This study confirms previous observations that tympanostomy tube insertion for OME varies markedly and demonstrates that although England had a lower mean rate than NNE, its variation in rates in England was much greater. 7, 8, 15 The magnitude of observed variations in procedure rates in both countries is unlikely to be explained by the regional differences in the incidence of OME and raises the question: "Which rate is right?" Using persistent OME and objective hearing loss as the best evidence-based assessment of likely benefit, this study provides indication of possible underuse in some areas of England and NNE, and possible overuse in other areas of NNE. However, these measures may overestimate the need for tympanostomy tubes insertion for 3 reasons.
First, the evidence for long-term benefit of tympanostomy tubes is weak. Historically, tympanostomy tube insertion was considered appropriate to prevent recurrent episodes of acute otitis media or for hearing loss from OME. 18, 19 Although OME spontaneously resolves for most children, a proportion of them suffer from persistent effusion that may cause impaired hearing which, in some children, can affect educational performance, language development, and/or behavior. 1, 25 Tympanostomy tubes for OME have been shown to reduce OME and improve hearing, but longer-term benefits have been harder to detect, 13, [20] [21] [22] particularly with regard to improved language and cognitive development. 13, 19 Therefore, even guidelines-based assessments of overuse and underuse may overestimate the benefit from tympanostomy tubes. 7, 8, 11, 20, 22 Second, with the exception of the use of tubes for reducing OME and improvement of hearing loss, 23 the 3 major guidelines are based largely on observational studies and professional opinion. 1, 16, 19 For example, a recent guideline recommends that "clinicians may perform tympanostomy tube insertion in atrisk children with unilateral or bilateral OME that is unlikely to resolve quickly as reflected by a type B (flat) tympanogram or persistence of effusion for 3 months or longer." 19 Risks are defined as "sensory, physical, cognitive, or behavioral factors that place children who have OME at increased risk for developmental difficulties (delay or disorder)." Even though the face validity of these recommendations seems high, the evidence supporting benefit remains limited. Broad definitions of the children likely to benefit adds to the potential for inadvertent overuse and underuse. In the same guidelines, it is recommended that Clinicians may perform tympanostomy tube insertion in children with unilateral or bilateral OME for 3 months or longer (chronic OME) AND symptoms that are likely attributable to OME that include, but are not limited to, balance (vestibular) problems, poor school performance, behavioral problems, ear discomfort, or reduced quality of life.
The 2 other current guidelines also suggest consideration of tube placement for at-risk children. 1, 16 In England, the majority of insertions were recommended on the basis of "exceptional circumstances." 20 Third and finally, audits suggest that many tube insertions may not be appropriate. A multicenter cohort study in New 
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York found that only 7.5% of tympanostomy tubes provided were concordant with clinical practice guidelines. 7 In England, a recent multicenter study found that only 32% of ear tubes were in concordance with the NICE criteria. 20 In England, epidemiologic modeling indicates that about 31 000 children would have benefited from the procedure (25 dB threshold), but only about 16 600 operations were undertaken. If the previous clinical audit study is accurate, 20 two-thirds of those 16 600 were not consistent with guidelines. In NNE, using the US 20 dB threshold, about 8000 children would have benefited from the procedure, but applying the findings of the New York State appropriateness study, 7 less than 1000 of the operations would have been consistent with guidelines.
Taken together, the lack of evidence for long-term benefit, the unavailability of clinical trials for the most common indications, and the low level of appropriateness of tube insertions are deeply troubling and raise questions about current utilization patterns. The overall lower rates of pressure equalization tube utilization in England likely reflects the greater degree of scrutiny of nonemergent procedures in a national health system with a fixed budget, and England's more "conservative" clinical practice guidelines. The widespread differences between utilization and estimated need (ie, expected procedures) indicate that population differences are unlikely to explain variation in use. The magnitude of the variation across both countries' regions indicate that differences in country-specific insurance systems, reimbursement policies or the organization of care are unlikely to be dominant factors in explaining the variation. Generally, research into the causes of regional variation into other procedures have found the primary determinant to be differences in physician practice styles reflecting professional uncertainty about the utility of the procedure in a given patient. This is compounded by the difficulty of physicians to diagnose patient and family decision preferences when medical care, watchful waiting, or procedures all have some degree of benefit and risk. [26] [27] [28] There are several limitations to the study. The first is the uncertainty of the model parameters. Even though tympanostomy tube insertion is a common pediatric procedure, many gaps remain in our knowledge of the natural history of OME and the benefit of treatment. 29 Population-based prevalence data of OME with hearing loss is not available for small areas, and are impractical to collect. To estimate these rates, we applied historical rates available in the literature to age-specific population counts. Since the advent of conjugate pneumococcal vaccines, the incidence of pneumococcal respiratory tract infections includes acute otitis media, recurrent acute otitis media, and persistent OME has decreased substantially in many countries. [30] [31] [32] The model does not include more detailed patient and caregiver characteristics or care preferences. The parameters of the model are, therefore, estimates of average expected procedures based upon the framework of current objectively based clinical guidelines. Additional subjective criteria cannot be modeled, such as children with special needs 1 or those with behavioral problems without evidence of hearing loss. 19 Nevertheless, the quality of evidence (ie, randomized clinical trials) for tympanostomy tube efficacy is strongest in those with hearing loss demonstrated with audiometry, 23 the criteria that we used in this study.
The observed number of tympanostomy tubes is limited to patients insured by Medicaid and commercial plans in NNE. The 3 states have somewhat different reporting requirements for commercial insurance and some children remain uninsured. Our data capture 92% of the pediatric population of Vermont, 80% of Maine, and about 70% of New Hampshire. 4 Maine Medicaid data from 2010 were not available at the time of this study. Observed number of tympanostomy tubes includes only patients treated in the NHS, and not those procedures paid for privately. Although the precise number is not known, the percentage of tonsillectomies, a procedure also performed by otolaryngologists in both countries, performed in United Kingdom private practice is estimated to be about 16% and total private sector expenditure on healthcare in the United Kingdom (2011) is 17.2%. 33 The lack of private practice data was unlikely to substantially affect the results of the study.
Although the epidemiologic risk for OME is multifactorial, and includes such factors as race, socioeconomic status, exposure to cigarette smoke, and daycare attendance, 21, 25, 34 our model does not include information on these patient and environmental characteristics. In NNE, the overall rates of tube placement by insurance type, a socioeconomic indicator, differs by only 5%, but this may not be an accurate indicator of the differing incidence of OME. The NNE children are less racially and ethnically diverse than the children of England, but the differences between NNE and England are small compared with NNE and other regions of the US. 35 Median household income is comparable between nations. 33, 35 Economic diversity in NNE is below the national mean as measured by income inequality. 35 The rate of the uninsured population is far below the US average, 35 but not as low as in England, where the entire resident population has access to care provided by the NHS. Although waiting times for surgery in the NHS are a concern for the period of our study, there was a median waiting time of 7.3 weeks (51 days) for tympanostomy tube insertion from the decision to perform the procedure. 36 This study is novel in its comparison in the use of tympanostomy tubes in regions of the US and in England in relation to the number expected from clinical practice guidelines based on persistent OME and objective measures of hearing loss. The observed rates differ markedly across small areas. Given the magnitude of discrepancy from expected rates, the variation is unlikely to be explained by variation in disease prevalence or need. Using our criteria as a standard of practice, these findings suggest likely overuse and underuse in NNE, and underuse in England. As the English and US guidelines differ and the longer-term benefits of tympanostomy tubes for OME have not been demonstrated, 21 rates based on guidelines may not be a useful guide of patient need. In this circumstance of uncertainty in benefits, implementation of shared decision making could be a useful companion to clinical practice guidelines by providing balanced information on treatment choices, and assisting patients and families in clarifying their health values and treatment goals. [37] [38] [39] [40] [41] Higher quality evidence on the benefits of tympanostomy tubes also would improve the decision making process. ■ All rates per 1000 child-years.
